Journal of advanced research
High-throughput screening identifies FDA approved drug mitiglinide as a novel pyroptosis inhibitor and therapeutic agent for osteoarthritis.
Hanwen Zhang, Tanxin Yu, Nanfang Zhuo, Zongxin Zhu, Shihan Lin, Shiying Zhao, Huilin Yu, Youli Zhang, Aimin Wu, Jiangning Wang, Yifei Zhou, Xiaolei Zhang
Published: 202510.1016/j.jare.2025.12.004
Abstract
INTRODUCTION: Osteoarthritis (OA), a leading cause of joint dysfunction, is characterized by progressive cartilage degradation linked to chondrocyte pyroptosis, yet disease-modifying therapies remain elusive. In this study, we conducted the first sys…
Preview only. Read the full abstract at the source